Nivolumab monotherapy after induction chemotherapy, bioradiotherapy, and cetuximab monotherapy leading to complete remission of locoregional advanced tongue cancer: A case report-Reference-Cited by-同舟云学术

Nivolumab monotherapy after induction chemotherapy, bioradiotherapy, and cetuximab monotherapy leading to complete remission of locoregional advanced tongue cancer: A case report

Published:2021-05-29 Issue:1 Volume:19 Page:72-76
ISSN:1348-8643
Container-title:Oral Science International
language:en
Short-container-title:Oral Science International

Author:

Yoshioka Yukio¹^ORCID,Hamana Tomoaki¹,Mishima Takefumi²,Tani Ryouji²,Toratani Shigeaki¹,Okamoto Tetsuji¹³

Affiliation:

1. Department of Molecular Oral Medicine and Maxillofacial Surgery Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

2. Department of Oral and Maxillofacial Surgery Hiroshima University Hospital Hiroshima Japan

3. School of Medical Sciences University of East Asia Shimonoseki Japan

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/osi2.1114

Reference13 articles.

1. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

2. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

3. Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report

4. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study

5. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Collagen cross‐linking in oral cancer;Oral Science International;2023-03-28

2. Enhanced degradation of epidermal growth factor receptor by metformin;Oral Science International;2023-03-05

3. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy;International Immunopharmacology;2022-12